GlassScriptPhysician profile
Thomas Milton Kay
NPI 1619294592
$4,378.38
in general payments reported to CMS, 2019-2025
13 companies · $261 in 2025
The $261 reported for 2025 was more than what 87% of Emergency Medicine providers received nationally (typical 2025 total: $57.10).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $62.78 · 2021: $1,267 · 2022: $2,413 · 2023: $47.13 · 2024: $328 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $635.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baudax Bio INC. | $3,657.82 | 2020-2022 | |
| Novo Nordisk INC | $135.60 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $135.29 | 2024-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $104.22 | 2023-2025 | |
| Corcept Therapeutics | $85.33 | 2024 | Korlym |
| Medtronic, INC. | $84.77 | 2022 | |
| Exact Sciences Corporation | $35.92 | 2024-2025 | Cologuard Collection Kit |
| Genzyme Corporation | $30.60 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.83 | 2024-2025 | Xifaxan |
| Abbvie INC. | $25.85 | 2023 | |
| Axsome Therapeutics, INC. | $20.71 | 2025 | Auvelity |
| Amgen INC. | $19.15 | 2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $15.29 | 2025 | Farxiga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.